Optimi Health Provides Corporate Update

Executive Summary

• Optimi Health Corp. received a Health Canada Drug Establishment Licence (DEL) inspection approval with no critical observations, granting GMP‑compliant authority to fabricate, label, package, distribute and wholesale pharmaceutical‑grade psychedelic products.
• The company announced a market‑making service agreement with Independent Trading Group (ITG) to provide liquidity for Optimi’s shares on the CSE and other venues, at a fee of CDN $6,500 per month.

Key Details

• DEL Inspection Outcome: Passed with no critical observations; GMP‑compliant rating awarded.
• Authorized Activities under DEL:
• Fabrication (API & pharmaceutical finished products)
• Labeling (API & pharmaceutical)
• Packaging (API & pharmaceutical)
• Distribution (pharmaceutical)
• Wholesale of Schedule G, narcotics, and cannabis‑related drugs.
• Current Product Use: MDMA capsules for PTSD and psilocybin capsules for treatment‑resistant depression are being prescribed in Australia under the Authorized Prescriber Scheme.
• Market‑Making Agreement:
• Parties: Optimi Health Corp. & Independent Trading Group (ITG)
• Effective Date: September 30, 2025 (subject to CSE approval)
• Services: Provide market‑making on the CSE and other venues to maintain an orderly market and improve liquidity.
• Compensation: CDN $6,500 per month; no performance‑based fees, shares, or options granted.
• Term: Initial one‑month term, automatically renewing monthly unless either party gives 30‑day notice of termination.
• Contact Information for Product Access: [email protected] (general); Mind Medicine Australia (Australia prescribers) – [email protected].

Notable Quotes

(No direct quotes were provided in the release.)